PHASEBIO PHARMACEUTICALS INC's ticker is PHAS and the CUSIP is 717224109. A total of 59 filers reported holding PHASEBIO PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $2,000 | -99.2% | 13,721 | -96.9% | 0.00% | – |
| Q2 2022 | $264,000 | -31.4% | 439,265 | +50.4% | 0.00% | -100.0% |
| Q1 2022 | $385,000 | -48.5% | 291,998 | +2.0% | 0.00% | 0.0% |
| Q4 2021 | $747,000 | -18.0% | 286,259 | -2.2% | 0.00% | 0.0% |
| Q3 2021 | $911,000 | -6.8% | 292,840 | +11.5% | 0.00% | 0.0% |
| Q2 2021 | $977,000 | +14.8% | 262,693 | +6.8% | 0.00% | 0.0% |
| Q1 2021 | $851,000 | +20.5% | 245,887 | +17.0% | 0.00% | 0.0% |
| Q4 2020 | $706,000 | +7.1% | 210,125 | +11.9% | 0.00% | 0.0% |
| Q3 2020 | $659,000 | -19.1% | 187,837 | +6.0% | 0.00% | -50.0% |
| Q2 2020 | $815,000 | +44.0% | 177,186 | -0.4% | 0.00% | 0.0% |
| Q1 2020 | $566,000 | -42.3% | 177,868 | +9.1% | 0.00% | 0.0% |
| Q4 2019 | $981,000 | +16.2% | 163,043 | -19.9% | 0.00% | 0.0% |
| Q3 2019 | $844,000 | -11.3% | 203,458 | +178.9% | 0.00% | 0.0% |
| Q2 2019 | $951,000 | – | 72,961 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Johnson & Johnson Innovation - JJDC, Inc. | 1,607,044 | $5,400,000 | 0.70% |
| NEA Management Company, LLC | 6,643,704 | $22,323,000 | 0.59% |
| DAFNA Capital Management LLC | 320,542 | $1,077,000 | 0.32% |
| Platform Technology Partners | 141,025 | $474,000 | 0.23% |
| Parkman Healthcare Partners LLC | 110,547 | $371,000 | 0.10% |
| Rock Springs Capital Management LP | 1,314,374 | $4,416,000 | 0.09% |
| GSA CAPITAL PARTNERS LLP | 140,341 | $472,000 | 0.08% |
| SABBY MANAGEMENT, LLC | 65,000 | $218,000 | 0.04% |
| Virtu Financial LLC | 28,821 | $97,000 | 0.01% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 127,600 | $429,000 | 0.01% |